系统性炎症标志物与晚期胃癌患者治疗ICI与化疗相结合的疗效之间的相关性
Qiuxia Dong1,2,3,4, Fuxing Zhao1,2,3,5, Yuying Li6
1Research Center for High Altitude Medicine, Qinghai University, Xining, People's Republic of China.
Immunology
|January 25, 2024
概括
系统性免疫炎症指数 (SII) 和血小板与淋巴细胞比率 (PLR) 预测了接受免疫检查点抑制剂 (ICI) 以及化疗的晚期胃癌患者的结果. 一个包含SII的名图有助于预测预后.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 胃肠病学 胃肠病学
背景情况:
- 先进的胃癌治疗缺乏免疫检查点抑制剂 (ICI) 与化疗相结合的预测生物标志物.
- 炎症标志物在预测晚期胃癌治疗疗效方面的作用仍未得到充分研究.
研究的目的:
- 研究系统性炎症标志物与ICI结合化疗在晚期胃癌中的疗效之间的相关性.
- 开发一种临床预测模型,用于该患者群体的生存结果.
主要方法:
- 对197名晚期胃癌患者的回顾性分析,这些患者接受了ICI加化疗 (2020年1月 - 2022年12月).
- 分析了系统性免疫炎症指数 (SII),中性粒细胞与淋巴细胞的比率 (NLR) 和血小板与淋巴细胞的比率 (PLR).
- 使用双向渐进回归构建了一个名图,并通过外部验证.
主要成果:
- 较低的SII和PLR与更高的整体存活率 (OS) 有关.
- SII,NLR,PLR和N阶段被确定为OS的独立预后因素.
- 基于SII的nomogram显示了对12个月的操作系统的良好预测性能.
结论:
- 基线SII,PLR和N阶段是接受ICI加化疗的晚期胃癌患者生存的独立预测因素.
- 开发的基于SII的诺米图为个人预后预测提供了一个直观而准确的工具.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
Gastritis III: Clinical Manifestations and Management
252
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
252
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
137
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
137
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
166
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
166
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
334
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
334
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
163
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
163


